NeoCore Business Summary

NeoCore Technology Co., Ltd. (4131.TWO), formerly known as Dr. Chip Biotechnology, operates a diversified biomedical revenue model centered on the design and manufacture of biochips and rapid nucleic acid hybridization devices. The company generates revenue through four primary segments: medical equipment sales (65%), in-vitro diagnostic (IVD) chips and reagents (17%), technical service fees (9%), and miscellaneous biotechnology products. Following its 2025 acquisition of Victory Eight Enterprise Co., Ltd., NeoCore has aggressively expanded into the medical aesthetics market, integrating dual-wavelength pulse technology and AI-driven diagnostic platforms into its portfolio. In the Taiwan-listed biotech landscape, NeoCore occupies a specialized niche in molecular detection and aesthetic hardware, competing alongside larger-cap entities such as PharmaEssentia (6446.TW), Caliway Biopharmaceuticals (6919.TW), Bora Pharmaceuticals (6472.TW), and Lotus Pharmaceutical (1795.TW). The company is currently led by Chairman Chou Ting-Mao (周鼎茂) and General Manager Chi Wen-Sheng (紀文勝), who have overseen the firm's strategic pivot toward precision medicine and automated laboratory solutions. Founded in 1998 by a team of molecular biology experts including former general manager Wang Hsien-Huang, NeoCore (originally Jing-Wei Biomedical) established its reputation through the development of cost-effective nylon-based biochips for infectious disease testing. The current leadership team brings a pedigree of industrial manufacturing and corporate restructuring, evidenced by the successful 2025 merger and the 2026 launch of Thin-prep Cytology (TCT) preservative solutions. Notable board influence includes institutional investors from recent private placements, such as representatives from the Broad-Tai Metal group, which has provided the capital necessary for NeoCore's expansion into AI-integrated medical robotics.